These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 15225830)
61. GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population. Zhou L; Zhang X; Chen X; Liu L; Lu C; Tang X; Shi J; Li M; Zhou M; Zhang Z; Xiao L; Yang M Int J Clin Exp Med; 2012; 5(1):72-9. PubMed ID: 22328951 [TBL] [Abstract][Full Text] [Related]
62. Resistance to 1,25D-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor. Garay E; Donnelly R; Wang X; Studzinski GP J Cell Physiol; 2007 Dec; 213(3):816-25. PubMed ID: 17520689 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma. Yu ZJ; Yu JW; Cai W; Yuan HX; Li XY; Yuan Y; Chen JP; Wu XY; Yao DF World J Gastroenterol; 2005 Sep; 11(33):5221-5. PubMed ID: 16127757 [TBL] [Abstract][Full Text] [Related]
64. Hepatic intra-arterial injection of lipiodol-1,25-dihydroxyvitamin D3 for hepatocellular carcinoma in rats. Jourdan JL; Akhter J; Bowrey P; Pourgholami M; Morris DL Anticancer Res; 2000; 20(4):2739-44. PubMed ID: 10953352 [TBL] [Abstract][Full Text] [Related]
65. The use of lipiodol and medium chain triglyceride as delivery agents for hepatic arterial administration of 1, 25-dihydroxyvitamin D3--a potential new treatment for hepatocellular carcinoma. Finlay IG; Stewart GJ; Pourgholami MH; Akhter J; Morris DL Anticancer Res; 2000; 20(4):2705-9. PubMed ID: 10953347 [TBL] [Abstract][Full Text] [Related]
66. 1,25-dihydroxyvitamin D3 dissolved in lipiodol produces a sustained antiproliferative effect in the human hepatoblastoma cell line HepG2. Pourgholami MH; Akhter J; Finlay IG; Morris DL Anticancer Res; 2000; 20(2A):723-7. PubMed ID: 10810346 [TBL] [Abstract][Full Text] [Related]
67. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma. Morris DL; Jourdan JL; Finlay I; Gruenberger T; The MP; Pourgholami MH Int J Oncol; 2002 Oct; 21(4):901-6. PubMed ID: 12239633 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Ghous Z; Akhter J; Pourgholami MH; Morris DL Anticancer Res; 2008; 28(6A):3757-61. PubMed ID: 19189661 [TBL] [Abstract][Full Text] [Related]
69. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. Pourgholami MH; Morris DL J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):513-8. PubMed ID: 15225830 [TBL] [Abstract][Full Text] [Related]
70. Therapy of hepatocellular cancer with iodine-131-Lipiodol. Risse JH; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H Rom J Gastroenterol; 2004 Jun; 13(2):119-24. PubMed ID: 15229776 [TBL] [Abstract][Full Text] [Related]
71. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
72. 131-iodine Lipiodol therapy in hepatocellular carcinoma. Raoul JL; Boucher E; Roland V; Garin E Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315 [TBL] [Abstract][Full Text] [Related]
73. [Recent advances in research on SMANCS]. Maeda H Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680 [TBL] [Abstract][Full Text] [Related]